Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
Emerald Health Pharmaceuticals (EHP), the company developing the synthetic cannabis-derived EHP-101 as a treatment for scleroderma, has been granted six patents related to 25 new molecules derived from cannabidiol (CBD) ... Read more
A pre-clinical stage preceding the development of digital ulcers could provide a window of opportunity for treatment before serious tissue damage occurs in people with scleroderma, according to a new ... Read more
The combination of three imaging techniques can provide a better understanding of structural and functional skin changes in the fingers, leading to an earlier and more accurate diagnosis of ... Read more
Intravenous antibodies can be used as add-on therapy to reduce the dosage of corticosteroids and achieve disease remission in people with scleroderma-associated myopathy (SScAM), or muscle disease, a study ... Read more
Evidence of pleuroparenchymal fibroelastosis (PPFE) — a rare type of interstitial lung disease — in people with systemic sclerosis (SSc) carries a negative prognosis, a study shows. Therefore, SSc ... Read more
While there are significant differences in how patients with juvenile localized scleroderma (JLS) are assessed and screened in the United Kingdom, treatment approaches are consistent, a study has found. ... Read more